title: Bladder cancer: can we move beyond chemotherapy?
abstract: Since the advent of cisplatin-based chemotherapy, cytotoxic combination chemotherapy remains the mainstay of treatment for locally advanced and metastatic urothelial malignancies. The current paradigm of combining novel agents with cytotoxic chemotherapy without any understanding of the underlying biology of urothelial cancer has limited the impact of developing novel agents for this disease. Current research investigating the biology of bladder cancer, including the role of p53, EMT, EGFR-related pathways, and anti-angiogenic pathways, may potentially impact the future development of novel agents targeting urothelial malignancies. Additionally, the use of novel gene therapy to mediate enhanced interferon expression in the bladder using adenoviral vectors, and enhancing tumor recognition strategies using the immune system with vaccines and anti-CTLA4 antibodies, are of interest. It is hoped that through these efforts we may soon move beyond the traditional cytotoxic chemotherapy paradigm, developing combinations that are more active and less toxic for all patients with urothelial cancer.
authors.affiliation: Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1155 Pressler Street, Houston, TX 77030, USA. asiefker@mdanderson.org
authors.forename: Arlene
authors.initials: A
authors.lastname: Siefker-Radtke
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D001749:Urinary Bladder Neoplasms / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D000093542:Gemcitabine
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003841:Deoxycytidine; D000068258:Bevacizumab; D002945:Cisplatin; D000093542:Gemcitabine
references.citation: Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3967-72
references.pmid: 17360461
references.citation: J Urol. 1985 Mar;133(3):403-7
references.pmid: 4038749
references.citation: Cancer Res. 1997 Dec 1;57(23):5281-5
references.pmid: 9393750
references.citation: Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):389-94
references.pmid: 17692556
references.citation: Clin Cancer Res. 2003 Jul;9(7):2583-6
references.pmid: 12855634
references.citation: J Clin Oncol. 2001 Oct 15;19(20):4005-13
references.pmid: 11600601
references.citation: J Clin Oncol. 2004 Jan 15;22(2):220-8
references.pmid: 14665607
references.citation: J Clin Oncol. 2009 Sep 1;27(25):4062-7
references.pmid: 19636012
references.citation: J Clin Oncol. 2000 Sep;18(17):3068-77
references.pmid: 11001674
references.citation: Clin Cancer Res. 2008 Mar 1;14(5):1478-86
references.pmid: 18316572
references.citation: J Clin Oncol. 1994 Mar;12(3):483-8
references.pmid: 7509853
references.citation: J Clin Oncol. 1995 Sep;13(9):2272-7
references.pmid: 7666085
references.citation: J Urol. 2001 Oct;166(4):1275-9
references.pmid: 11547057
references.citation: J Immunother. 2008 Nov-Dec;31(9):849-57
references.pmid: 18833002
references.citation: Clin Cancer Res. 1995 Oct;1(10):1189-94
references.pmid: 9815911
references.citation: J Urol. 2004 Feb;171(2 Pt 1):570-4
references.pmid: 14713761
references.citation: J Natl Cancer Inst. 2008 Oct 1;100(19):1401-11
references.pmid: 18812553
references.citation: Clin Cancer Res. 2006 Aug 1;12(15):4671-7
references.pmid: 16899617
references.citation: J Clin Oncol. 1993 Mar;11(3):408-14
references.pmid: 7680373
references.citation: Cancer Immun. 2003 Dec 18;3:19
references.pmid: 14680360
references.citation: Clin Cancer Res. 2009 Aug 15;15(16):5060-72
references.pmid: 19671845
references.citation: Clin Cancer Res. 2001 Aug;7(8):2440-7
references.pmid: 11489824
references.citation: J Natl Cancer Inst. 1995 Nov 1;87(21):1603-12
references.pmid: 7563203
references.citation: J Urol. 2009 Sep;182(3):907-13
references.pmid: 19616250
references.citation: Eur J Surg Oncol. 2006 May;32(4):439-44
references.pmid: 16517112
references.citation: Cancer. 2000 Apr 1;88(7):1671-8
references.pmid: 10738226
references.citation: Anticancer Res. 1994 May-Jun;14(3B):1317-24
references.pmid: 7915094
references.citation: Mol Ther. 2004 Sep;10(3):525-32
references.pmid: 15336652
references.citation: J Clin Oncol. 2009 Jun 1;27(16):2592-7
references.pmid: 19414678
references.citation: Stat Med. 2000 Apr 30;19(8):1011-28
references.pmid: 10790677
references.citation: Am J Clin Pathol. 1994 Feb;101(2):166-76
references.pmid: 7906919
references.citation: J Clin Oncol. 2001 May 15;19(10):2638-46
references.pmid: 11352955
references.citation: Urol Oncol. 2004 Jan-Feb;22(1):1-6
references.pmid: 14969795
references.citation: J Clin Oncol. 1990 Jun;8(6):1050-5
references.pmid: 2189954
references.citation: J Clin Oncol. 2002 Mar 1;20(5):1361-7
references.pmid: 11870180
references.citation: N Engl J Med. 2003 Aug 28;349(9):859-66
references.pmid: 12944571
references.citation: J Natl Cancer Inst. 2002 Sep 4;94(17):1320-9
references.pmid: 12208897
references.citation: J Urol. 2003 Apr;169(4):1295-8
references.pmid: 12629346